Pharmafile Logo

News and Press Releases

Recipharm supports landmark trial of next generation pneumococcal vaccine developed by ImmBio and iiCON

Recipharm delivers cGMP manufacture of PnuBioVax® enabling progression to phase 2 clinical trials in Malawi Demonstrates Recipharm’s agility and flexibility, completing full tech transfer, scale-up and process optimisation within three...

Category: BioManufacturing, Drug Delivery, Manufacturing and Packing, Other, Pharmaceutical
Posted: October 15, 2025

argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy

VYVGART® SC, first-and-only IgG Fc-antibody fragment which specifically targets the neonatal Fc receptor (FcRn), now approved for use in Europe for CIDP Approval based on ADHERE clinical trial, the largest...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: June 20, 2025

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria

Approval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placebo In the US, there are more than 300,000 adults and adolescents aged 12 years...

Category: Biotechnology, Clinical Trials, Other, Pharmaceutical
Posted: April 18, 2025

Regeneron
ukinfo@regeneron.com
The Charter Building, Vine Street, Uxbridge, Middlesex, United Kingdom, UB8 1JG

Sanofi to acquire Dren Bio’s bispecific myeloid cell engager for deep B-cell depletion, broadening immunology pipeline

Dren Bio deep B-cell depleter program has the potential to reset the immune system Acquisition underpins path for Sanofi becoming leading immunology company Sanofi to pay $600 million up front....

Category: Biotechnology, Clinical Trials, Drug Discovery, Other, Pharmaceutical
Posted: March 20, 2025

Sanofi
One Onslow Street, Guildford, Surrey, GU1 4YS, UK

UK’s MHRA grants Promising Innovative Medicine designation to argenx’ investigational therapy, subcutaneous efgartigimod alfa for the treatment of chronic inflammatory demyelinating polyneuropathy (CIDP)

28 November 2024 -- Gerrards Cross, UK -- argenx, a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, confirmed today that its investigational...

Category: Biotechnology, Drug Discovery, Other, Pharmaceutical
Posted: November 28, 2024

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG

Biogen Bolsters Late-Stage Pipeline, Expands Immunology Portfolio with Agreement to Acquire Human Immunology Biosciences

Transaction to include felzartamab, a potential first-in-class therapeutic candidate with promise as a pipeline-in-a-product across a range of immune-mediated diseases Felzartamab is an investigational anti-CD38 monoclonal antibody that, through its...

Category: Drug Discovery, Pharmaceutical
Posted: May 22, 2024

Biogen
Biogen International GmbH Neuhofstrasse 30 6340 Baar Switzerland

Gyros Protein Technologies introduces Gyrolab Generic Rodent ADA Kit Reagents to support preclinical immunogenicity assessment

Ready-to-use kit expands range of bioanalysis kits, and enables generic detection of immune complexes in rodent samples 2 May 2024 -- Uppsala, Sweden -- Gyros Protein Technologies, a pioneer in...

Category: BioManufacturing, Drug Discovery
Posted: May 2, 2024

Gyros Protein Technologies
information@gyros.com
Gyros AB, Uppsala Science Park, SE-751, 83 Uppsala, Sweden

argenx Announces MHRA Licensing of Subcutaneous VYVGART (efgartigimod alfa) for generalised Myasthenia Gravis

VYVGART is now licensed for both intravenous (IV) and self-administered subcutaneous (SC) use in the UK 7 February 2024 -- Gerrards Cross, UK -- argenx UK, part of argenx, a...

Category: Biotechnology
Posted: February 7, 2024

argenx
ukmediainfo@argenx.com
Spaces Gerrards Cross Chalfont Park, Building 1 Gerrards Cross, SL9 0BG